Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702534 | Urologic Oncology: Seminars and Original Investigations | 2017 | 9 Pages |
Abstract
Patients receiving EBRT for low-risk prostate cancer suffer declines in bowel HRQoL. These declines are not experienced by patients on AS, suggesting that management of low-risk prostate cancer with AS may offer a means for preserving HRQoL following prostate cancer diagnosis.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
John S. M.D., Lauren M. M.H.S., Jennifer Ph.D., M.P.H., Erika M. Ph.D., Katherine E. C.C.R.P., Inger L. M.D., Timothy C. M.D., James O. M.D., Joseph R. M.D., Christopher R. M.D., F.A.C.S.,